Restasis, Cequa, and Xiidra are prescription eye drops designed to treat dry eye disease by targeting the underlying inflammation that over-the-counter artificial tears cannot address.
This guide covers how each medication works, how they compare in efficacy and cost, their side effect profiles, candidate suitability, and practical guidance for starting and combining treatments.
Restasis and Cequa both use cyclosporine as a calcineurin inhibitor immunosuppressant, but at different concentrations and through different delivery systems. Restasis delivers 0.05% cyclosporine in an emulsion, while Cequa uses nanomicellar technology to deliver a higher 0.09% concentration. Xiidra takes a distinct approach as an LFA-1 antagonist, blocking the inflammatory protein interaction that damages the ocular surface.
Comparing the three involves more than mechanism. Generic Restasis may be available for under $100 at some pharmacies, while brand-name Xiidra often exceeds $800. Manufacturer savings programs may reduce costs to as little as $0 for eligible patients on both Restasis and Xiidra. Side effects differ as well; Restasis is most associated with ocular burning, Cequa with instillation pain, and Xiidra with an unusual taste change called dysgeusia.
Candidacy depends on individual factors including inflammation severity, prior treatment response, and insurance coverage. Patients who have not responded to one cyclosporine formulation may benefit from switching to a higher concentration or to lifitegrast’s distinct pathway.
Timing also matters for surgical patients. Untreated dry eye can distort preoperative measurements for cataract surgery, so addressing ocular surface health before a procedure may help protect visual outcomes.
What Is Dry Eye Disease and Why May It Require Prescription Treatment?
Dry eye disease is a multifactorial condition of the ocular surface in which tear film instability, inflammation, and neurosensory abnormalities disrupt normal eye function. Prescription treatment may be required when OTC artificial tears fail to address the underlying inflammatory processes driving the disease.
What Is Dry Eye Disease?
Dry eye disease is a chronic ocular surface condition characterized by a loss of tear film homeostasis, accompanied by symptoms such as burning, stinging, and blurred vision. According to the American Academy of Ophthalmology, its causes include tear film instability, hyperosmolarity, ocular surface inflammation and damage, and neurosensory abnormalities. These overlapping mechanisms explain why the condition varies so widely between patients. As Christopher E. Starr, MD, FACS, Associate Professor of Ophthalmology at Weill Cornell Medicine, notes: “Ocular surface disease is so complex, it almost warrants its own subspecialty. The bread and butter of dry-eye treatment revolves around the diagnosis.”
Why May Dry Eye Disease Require Prescription Treatment?
Dry eye disease may require prescription treatment when inflammation is the primary driver and over-the-counter options no longer provide adequate relief. Xiidra (lifitegrast ophthalmic solution 5%), for example, is an LFA-1 antagonist indicated specifically for the signs and symptoms of dry eye disease, targeting the inflammatory cascade at a molecular level. Mina Massaro-Giordano, MD, co-director of the University of Pennsylvania’s Dry Eye and Ocular Surface Center, explains: “The challenge is homing in on the right ones to tailor your treatment, which requires constant monitoring and management, usually with more than one medication.” Prescription options like Restasis, Cequa, and Xiidra address root causes that lubricating drops cannot.
How Does Restasis Work to Treat Dry Eye?
Restasis works by suppressing ocular surface inflammation to help restore the eye’s natural ability to produce tears. The sections below cover its active ingredient, how long results typically take, and how it is applied.
What Is the Active Ingredient in Restasis?
The active ingredient in Restasis is cyclosporine ophthalmic emulsion 0.05%. Cyclosporine is a calcineurin inhibitor immunosuppressant, meaning it targets the inflammatory pathway responsible for suppressing tear gland function. According to the FDA, Restasis is indicated to increase tear production in patients whose tear production is presumed to be suppressed due to ocular inflammation associated with keratoconjunctivitis sicca. The formulation is an emulsion, giving it a slightly thicker, milky consistency compared to other prescription dry eye drops.
How Long Does Restasis Take to Show Results?
Restasis typically takes about 6 months of consistent use for most patients to notice improved tear production, though some individuals may experience effects within as little as 1 month, according to GoodRx. The gradual timeline reflects how the medication works: rather than providing immediate lubrication, it steadily reduces underlying inflammation over weeks and months. Patients should continue use as directed even without immediate relief, since early discontinuation is a common reason treatment fails.
How Is Restasis Applied and Dosed?
Restasis is applied as one drop in each affected eye twice daily, approximately 12 hours apart. Each single-use vial should be inverted and shaken before instillation, and any remaining solution should be discarded after use. Contact lenses, if worn, should be removed before applying the drops and may be reinserted 15 minutes afterward. Consistent twice-daily dosing is essential for the anti-inflammatory mechanism to remain active and deliver cumulative benefit.
How Does Cequa Work to Treat Dry Eye?
Cequa works by delivering cyclosporine directly to the ocular surface using a proprietary nanomicellar technology that overcomes the drug’s poor water solubility. The H3s below cover its active ingredient, how its formulation differs from Restasis, expected onset of results, and dosing instructions.
What Is the Active Ingredient in Cequa?
The active ingredient in Cequa is cyclosporine, a calcineurin inhibitor immunosuppressant. Cequa delivers cyclosporine at a concentration of 0.09% in an aqueous solution, targeting the inflammatory pathways that suppress tear production in dry eye disease. By inhibiting T-cell activation on the ocular surface, it helps restore the eye’s natural tear-producing capacity over time.
How Does Cequa Differ From Restasis in Formulation?
Cequa differs from Restasis in both concentration and delivery technology. According to a study published on PubMed, Cequa contains 0.09% cyclosporine compared to Restasis’s 0.05%, and uses a nanomicellar solution rather than an emulsion. Sun Pharma’s NCELL nanomicellar technology encapsulates cyclosporine in tiny micelles, allowing it to travel through the aqueous tear film and penetrate the ocular surface more effectively than the oil-based emulsion used in Restasis.
How Long Does Cequa Take to Show Results?
Cequa may take up to three months to produce noticeable improvements in dry eye signs. In a Phase 3, randomized, double-masked clinical study of OTX-101 (the formulation used in Cequa), significant improvements in corneal staining were observed at days 28, 56, and 84 compared to vehicle, suggesting measurable changes can begin within the first month of consistent use. Patients should be counseled that full therapeutic benefit typically requires continued use over several months.
How Is Cequa Applied and Dosed?
Cequa is applied as one drop instilled into each eye twice daily, approximately 12 hours apart. The most common adverse reactions reported in greater than 5% of patients were pain on instillation (22%) and conjunctival hyperemia (6%), according to Cequa prescribing data. Contact lenses should be removed before instillation and may be reinserted 15 minutes afterward. Consistent twice-daily dosing is important for achieving the anti-inflammatory benefit Cequa is designed to provide.
How Does Xiidra Work to Treat Dry Eye?
Xiidra works by blocking a specific inflammatory protein interaction on the ocular surface, making it mechanistically distinct from cyclosporine-based drops. The following sections cover Xiidra’s active ingredient, how its mechanism differs from cyclosporine, how quickly it works, and how it is applied.
What Is the Active Ingredient in Xiidra?
The active ingredient in Xiidra is lifitegrast ophthalmic solution 5%. Lifitegrast is a lymphocyte function-associated antigen-1 (LFA-1) antagonist, meaning it blocks LFA-1 from binding to intercellular adhesion molecule-1 (ICAM-1), a key step in the inflammatory cascade that damages the ocular surface in dry eye disease.
How Does Xiidra’s Mechanism Differ From Cyclosporine Drops?
Xiidra’s mechanism differs from cyclosporine drops in its molecular target. Cyclosporine (used in Restasis and Cequa) works as a calcineurin inhibitor, suppressing T-cell activation broadly. Lifitegrast, by contrast, directly blocks the LFA-1/ICAM-1 interaction at the ocular surface, interrupting the inflammation signal more upstream. This targeted approach means Xiidra addresses both the signs and symptoms of dry eye through a distinct pathway, which is why some patients unresponsive to cyclosporine may respond better to lifitegrast.
How Long Does Xiidra Take to Show Results?
Xiidra may begin to relieve symptoms within two weeks for some patients, though meaningful improvements in both signs and symptoms typically develop over several weeks. According to data from Xiidra Professional, patients achieved significantly longer comfortable contact lens wear time versus baseline, increasing from 6.5 hours to 9.1 hours at 12 weeks. This lens wear improvement is a practical, patient-centered indicator that ocular surface inflammation is responding to treatment.
How Is Xiidra Applied and Dosed?
Xiidra is applied as one drop in each eye twice daily, approximately 12 hours apart. The solution comes in single-use dispensers, which should be discarded after each use. Contact lenses should be removed before instillation and may be reinserted 15 minutes afterward.
With a clear picture of how Xiidra works, comparing it directly against Restasis and Cequa helps clarify which option may suit different patients best.
How Do Restasis, Cequa, and Xiidra Compare to Each Other?
Restasis, Cequa, and Xiidra differ in active ingredient, formulation, onset of action, cost, and side effect profile. The sections below compare efficacy, pricing, and tolerability across all three medications.
How Does Efficacy Compare Among Restasis, Cequa, and Xiidra?
Efficacy among Restasis, Cequa, and Xiidra varies by mechanism and concentration. Restasis and Cequa both use cyclosporine to suppress ocular surface inflammation, but Cequa contains a higher concentration (0.09%) compared to Restasis (0.05%) and uses a nanomicellar solution rather than an emulsion, according to a PubMed concentration study. Xiidra targets a different pathway entirely, blocking LFA-1 to interrupt the inflammatory signaling cycle rather than acting as a calcineurin inhibitor. No head-to-head clinical trial directly ranks one above the others in overall efficacy, so the most effective option for a given patient typically depends on their specific inflammatory profile and tolerance.
How Does Cost and Insurance Coverage Compare?
Cost and insurance coverage differ meaningfully across the three medications. Restasis has the lowest out-of-pocket floor: generic cyclosporine 0.05% is available at certain pharmacies for as little as $94.07 with a GoodRx coupon, while brand-name Xiidra typically costs over $800 and is usually classified as Tier 3 or 4. Cequa has no generic alternative. Patient assistance programs can reduce costs significantly: eligible commercially insured patients may pay as little as $0 for Restasis or Xiidra through their respective manufacturer savings programs. Cost is an often-underestimated factor in long-term treatment adherence, making it a practical consideration alongside clinical suitability.
How Do Side Effect Profiles Compare?
The side effect profiles of Restasis, Cequa, and Xiidra overlap in some areas but differ in key ways. Restasis most commonly causes ocular burning, with 17% of patients reporting it in clinical trials per FDA labeling. Cequa’s most frequent adverse reactions are instillation pain (22%) and conjunctival hyperemia (6%). Xiidra’s distinguishing side effect is dysgeusia, an unusual taste change, alongside instillation site irritation and temporary blurred vision. All three can cause transient discomfort on instillation. Patients who cannot tolerate one medication’s specific side effects may find another more manageable, making tolerability as clinically relevant as efficacy when choosing between these options.
What Are the Possible Side Effects of Prescription Dry Eye Drops?
The possible side effects of prescription dry eye drops vary by medication, with each formula carrying a distinct tolerability profile. The H3 sections below cover the most commonly reported reactions for Restasis, Cequa, and Xiidra.
What Are the Common Side Effects of Restasis?
The common side effects of Restasis include ocular burning, discharge, eye pain, foreign body sensation, stinging, and visual disturbance. According to FDA clinical trial data, ocular burning was the most frequently reported adverse reaction, occurring in 17% of patients. These reactions typically occur at the moment of instillation and tend to diminish over time as the eye adjusts to the emulsion formulation.
Most patients may notice improved tear production after approximately 6 months of consistent use, though some may see a response within 1 month. Given that tolerance often improves with continued use, many patients benefit from staying with the treatment through an initial adjustment period.
What Are the Common Side Effects of Cequa?
The common side effects of Cequa include pain on instillation and conjunctival hyperemia, or redness. In clinical data published by the manufacturer, pain on instillation was reported in 22% of patients and conjunctival hyperemia in 6%. These are the two adverse reactions occurring in greater than 5% of patients in clinical trials. Because Cequa uses a nanomicellar solution at a higher cyclosporine concentration than Restasis, instillation discomfort may be more pronounced for some patients.
What Are the Common Side Effects of Xiidra?
The common side effects of Xiidra include instillation site irritation, dysgeusia (a temporary altered or metallic taste sensation), and temporarily reduced visual acuity. According to the FDA-approved Xiidra prescribing label, these reactions were reported in 5 to 25% of patients in clinical trials. Dysgeusia is a distinctive side effect not associated with Restasis or Cequa and results from the drop travelling through the nasolacrimal duct. Patients who find the taste sensation bothersome may manage it by applying gentle pressure to the inner corner of the eye after instillation.
Understanding the side effect profile of each medication can help patients set realistic expectations and discuss tolerability concerns with their eye care provider before starting treatment.
Who May Be a Good Candidate for Prescription Dry Eye Drops?
Good candidates for prescription dry eye drops are patients whose symptoms persist despite artificial tears and over-the-counter options. The following sections cover who may benefit most from Restasis, Cequa, or Xiidra, and who should avoid these medications.
Who May Benefit Most From Restasis?
Patients who may benefit most from Restasis are those with chronic dry eye caused by inflammation-related tear production suppression, particularly keratoconjunctivitis sicca. It is a suitable consideration for commercially insured patients, as most eligible commercially insured patients may pay as little as $0 for a 90-day supply through the RESTASIS Savings Program. Patients who prefer an established, FDA-approved therapy with a long safety record and generic availability may also find Restasis a practical first prescription option.
Who May Benefit Most From Cequa?
Patients who may benefit most from Cequa are those who need cyclosporine therapy but have not responded adequately to lower-concentration formulations. Cequa contains 0.09% cyclosporine, a higher concentration than Restasis, delivered via nanomicellar technology that enhances ocular surface penetration. It may be worth discussing with an eye care provider for patients who tolerate cyclosporine but require stronger corneal surface coverage.
Who May Benefit Most From Xiidra?
Patients who may benefit most from Xiidra are those seeking symptom relief alongside sign improvement, particularly discomfort and eye dryness ratings. Xiidra targets the LFA-1 inflammatory pathway, a distinct mechanism from cyclosporine-based drops, making it a reasonable option for patients who have not responded to cyclosporine therapy. Contact lens wearers experiencing reduced comfortable wear time may also be appropriate candidates to discuss Xiidra with their provider.
Who Should Avoid Prescription Dry Eye Medications?
Patients who should avoid prescription dry eye medications include those with known hypersensitivity to any active ingredient, such as cyclosporine in Restasis or Cequa, or lifitegrast in Xiidra. Active ocular infections also contraindicate use of these medications. Pregnant or nursing patients should consult their provider before starting any prescription eye drop, as safety data in these populations is limited. A thorough evaluation by an eye care professional is essential before initiating any of these therapies.
What Should You Expect When Starting a Prescription Dry Eye Drop?
Starting a prescription dry eye drop involves an adjustment period, realistic timeline expectations, and awareness of early side effects. Patients typically experience temporary discomfort before noticing therapeutic benefit, and consistency with dosing is essential for the medications to work as intended.
Most prescription dry eye drops cause some degree of instillation discomfort in the first few weeks. Burning or stinging upon application is the most commonly reported early reaction across Restasis, Cequa, and Xiidra. According to FDA-reviewed clinical trial data, ocular burning occurred in 17% of Restasis users, while Cequa reported instillation pain in 22% of patients. Xiidra users may also notice dysgeusia, an unusual taste sensation, shortly after applying drops. These reactions are generally temporary and tend to lessen as the eyes adjust to treatment.
Timeline expectations vary by medication. GoodRx notes that most patients using Restasis see improved tear production after approximately six months, though some may notice early effects within one month. Xiidra may show symptom improvement sooner for some patients. Setting realistic expectations from the start helps patients stay consistent through the early weeks when discomfort is highest and benefits are not yet apparent.
A few practical considerations apply regardless of which drop is prescribed:
- Apply drops twice daily, approximately 12 hours apart, as directed.
- If using artificial tears concurrently, wait at least 15 minutes between applications.
- Do not touch the dropper tip to the eye or any surface to avoid contamination.
- Contact lens wearers should remove lenses before instillation and wait 15 minutes before reinserting them.
Adherence is often underestimated as a factor in treatment success. In clinical practice, patients who discontinue use early due to initial discomfort miss the therapeutic window these anti-inflammatory medications require. Staying consistent through the adjustment period is one of the most actionable steps toward meaningful improvement.
Can You Use Prescription Dry Eye Drops With Other Treatments?
Yes, you can use prescription dry eye drops with other treatments, and most ophthalmologists recommend a layered approach for moderate to severe dry eye disease. The sections below cover how prescription drops combine with artificial tears, warm compresses, and in-office procedures.
Can You Use Restasis, Cequa, or Xiidra With Artificial Tears?
Yes, you can use Restasis, Cequa, or Xiidra alongside artificial tears, though timing matters. Artificial tears should be instilled at least 15 minutes before or after a prescription drop to avoid diluting the active ingredient and reducing its effectiveness. This spacing helps preserve the therapeutic concentration of cyclosporine or lifitegrast on the ocular surface. For patients managing both products throughout the day, establishing a consistent schedule improves adherence and reduces the chance of inadvertent drop mixing.
Can You Combine Prescription Drops With Warm Compresses or Lid Hygiene?
Yes, you can combine prescription dry eye drops with warm compresses and lid hygiene routines. Meibomian gland dysfunction is a frequent co-contributor to dry eye, and warm compresses address the evaporative component that cyclosporine and lifitegrast do not directly target. Mina Massaro-Giordano, MD, co-director of the University of Pennsylvania’s Dry Eye and Ocular Surface Center, has noted that dry eye treatment “usually” requires more than one medication or modality. Using lid hygiene alongside prescription drops targets both the inflammatory and evaporative drivers of the condition simultaneously.
Can Prescription Dry Eye Drops Be Used Alongside In-Office Procedures?
Yes, prescription dry eye drops can be used alongside in-office procedures such as LipiFlow, intense pulsed light therapy, and punctal plugs. These procedures address meibomian gland obstruction or reduce tear drainage, while Restasis, Cequa, and Xiidra address underlying ocular surface inflammation. Combining approaches is particularly common in patients who show incomplete response to drops alone. In clinical practice, prescription drops often serve as the pharmacological foundation, with procedural therapies layered in to address structural or glandular contributors that medication cannot resolve on its own.
How Should You Discuss Dry Eye Treatment With Your Eye Surgeon?
Discussing dry eye treatment with your eye surgeon matters most when surgery is on the horizon. The subsections below cover how cataract surgery planning can address underlying dry eye and the key takeaways about Restasis, Cequa, and Xiidra.
Can Cataract Surgery Planning Address Underlying Dry Eye?
Yes, cataract surgery planning can and should address underlying dry eye. According to Dr. Preeya K. Gupta of Triangle Eye Consultants and Duke University Hospital, “It is important to consider ocular surface diseases before cataract surgery because they can alter measurements and have a significant refractive impact.” Untreated dry eye may distort keratometry values and astigmatism readings, leading to suboptimal intraocular lens selection. Treating dry eye before surgery can improve both visual outcomes and patient satisfaction, with one study showing 52% of patients had no corneal staining after 28 days of Xiidra treatment.
What Are the Key Takeaways About Restasis, Cequa, and Xiidra?
The key takeaways about Restasis, Cequa, and Xiidra are that all three are prescription anti-inflammatory options, but they differ in mechanism, formulation, and onset. Patients considering any of these medications should discuss their surgical timeline, current ocular surface health, and insurance coverage with their eye care provider. Selecting the right treatment depends on individual factors such as inflammation severity, prior treatment history, and cost. Starting treatment early, particularly before planned cataract surgery, may help protect measurement accuracy and support better long-term outcomes.
